Monetary Management Group Inc Bristol Myers Squibb CO Transaction History

Monetary Management Group Inc

$433 Million
Q3 2025

A detailed history of Monetary Management Group Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Monetary Management Group Inc holds 15,405 shares of BMY stock, worth $721,108. This represents 0.16% of its overall portfolio holdings.

Number of Shares

15,405

Previous 16,405 6.1%

Holding current value

$721,108

Previous $759,000 8.56%

% of portfolio

0.16%

Previous 0.19%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$43.31 - $48.98 $43,310 - $48,980	-1,000 Reduced 6.1%	15,405 $694,000
Q2 2025 Aug 14, 2025	SELL	$44.12 - $59.6 $22,060 - $29,800	-500 Reduced 2.96%	16,405 $759,000
Q4 2024 Feb 13, 2025	SELL	$51.92 - $59.94 $38,940 - $44,955	-750 Reduced 4.25%	16,905 $956,000
Q3 2024 Nov 13, 2024	SELL	$39.66 - $51.75 $65,240 - $85,128	-1,645 Reduced 8.52%	17,655 $913,000
Q2 2024 Jul 16, 2024	SELL	$40.25 - $52.99 $4,025 - $5,299	-100 Reduced 0.52%	19,300 $801,000

Q1 2024 May 13, 2024	SELL	$47.98 - $54.4 $34,785 - $39,440	-725 Reduced 3.6%	19,400 $1.05 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $176,952 - $211,152	-3,650 Reduced 15.35%	20,125 $1.03 Million
Q3 2023 Nov 09, 2023	SELL	$57.89 - $64.73 $176,101 - $196,908	-3,042 Reduced 11.34%	23,775 $1.38 Million
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $132,198 - $146,785	-2,075 Reduced 7.18%	26,817 $1.71 Million
Q1 2023 May 11, 2023	BUY	$65.71 - $74.53 $197,129 - $223,590	3,000 Added 11.59%	28,892 $2 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $51,360 - $60,817	-750 Reduced 2.82%	25,892 $1.86 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $13 - $7,684	-100 Reduced 0.37%	26,642 $1.89 Million
Q1 2022 May 12, 2022	SELL	$61.48 - $73.72 $53,795 - $64,505	-875 Reduced 3.17%	26,742 $1.95 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $76,422 - $89,091	1,425 Added 5.44%	27,617 $1.72 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $133,132 - $155,947	2,250 Added 9.4%	26,192 $1.55 Million
Q2 2021 Aug 12, 2021	SELL	$61.91 - $67.42 $772,017 - $840,727	-12,470 Reduced 34.25%	23,942 $1.6 Million
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $504,390 - $567,290	-8,500 Reduced 18.93%	36,412 $2.3 Million
Q4 2020 Feb 12, 2021	BUY	$57.74 - $65.43 $5,774 - $6,543	100 Added 0.22%	44,912 $2.79 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $192,103 - $212,875	-3,345 Reduced 6.95%	44,812 $2.7 Million
Q2 2020 Aug 13, 2020	BUY	$54.82 - $64.09 $58,657 - $68,576	1,070 Added 2.27%	48,157 $2.83 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $178,640 - $259,605	3,850 Added 8.9%	47,087 $2.63 Million
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $488,802 - $637,599	-9,933 Reduced 18.68%	43,237 $2.78 Million
Q3 2019 Nov 12, 2019	BUY	$42.77 - $50.71 $522,863 - $619,929	12,225 Added 29.86%	53,170 $2.7 Million
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $79,825 - $88,269	-1,789 Reduced 4.19%	40,945 $1.86 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $27,072 - $32,280	600 Added 1.42%	42,734 $2.04 Million
Q4 2018 Feb 13, 2019	SELL	$48.76 - $63.23 $24,380 - $31,615	-500 Reduced 1.17%	42,134 $2.19 Million
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $15,177 - $17,118	275 Added 0.65%	42,634 $2.65 Million
Q2 2018 Aug 13, 2018	SELL	$50.53 - $62.98 $5,053 - $6,298	-100 Reduced 0.24%	42,359 $2.34 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $35,964 - $39,210	600 Added 1.43%	42,459 $2.6 Million
Q3 2017 Nov 13, 2017	SELL	$55.23 - $63.74 $4,142 - $4,780	-75 Reduced 0.18%	41,859 $2.67 Million
Q2 2017 Aug 14, 2017	BUY	N/A	41,934	41,934 $2.34 Million

Others Institutions Holding BMY

# of Institutions

2,709

Shares Held

1.58B

Call Options Held

28M

Put Options Held

28.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Monetary Management Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Monetary Management Group Inc with notifications on news.

Account

Monetary Management Group Inc Bristol Myers Squibb CO Transaction History